Biology of Blood and Marrow Transplantation
Volume 10, Issue 4 , Pages 259-268 , April 2004

Antiviral immunity and T-regulatory cell function are retained after selective alloreactive T-cell depletion in both the HLA-identical and HLA-mismatched settings

  • Jeffrey K. Davies

      Affiliations

    • Department of Haematology, Royal Free & University College Medical School, London, United Kingdom UK
    • Corresponding Author InformationCorrespondence and reprint requests: J.K. Davies, MRCP, MRCPath, Department of Haematology, Royal Free Campus, Royal Free & University College Medical School, London NW3 2PF, UK
    • ,
  • Mickey B.C. Koh

      Affiliations

    • Department of Haematology, Royal Free & University College Medical School, London, United Kingdom UK
    • ,
  • Mark W. Lowdell

      Affiliations

    • Department of Haematology, Royal Free & University College Medical School, London, United Kingdom UK

Received 1 October 2003 ,Accepted 1 December 2003.

References 

  1. Atkinson K, Farrelly H, Cooley M, O’Flaherty E, Downs K, Biggs J. Human marrow T cell dose correlates with severity of subsequent acute graft-versus-host disease. Bone Marrow Transplant. 1987;2:51–57
  2. Ash RC, Casper JT, Chitambar CR, et al.  Successful allogeneic transplantation of T-cell-depleted bone marrow from closely HLA-matched unrelated donors. N Engl J Med. 1990;322:485–494
  3. Aversa F, Tabilio A, Velardi A, et al.  Treatment of high-risk acute leukemia with T-cell-depleted stem cells from related donors with one fully mismatched HLA haplotype. N Engl J Med. 1998;339:1186–1193
  4. Keever CA, Small TN, Flomenberg N, et al.  Immune reconstitution following bone marrow transplantation (comparison of recipients of T-cell depleted marrow with recipients of conventional marrow grafts). Blood. 1989;73:1340–1350
  5. Koh MB, Prentice HG, Lowdell MW. Selective removal of alloreactive cells from haematopoietic stem cell grafts (graft engineering for GVHD prophylaxis). Bone Marrow Transplant. 1999;23:1071–1079
  6. Koh MB, Prentice HG, Corbo M, Morgan M, Cotter FE, Lowdell MW. Alloantigen-specific T-cell depletion in a major histocompatability complex fully mismatched murine model provides effective graft-versus-host disease prophylaxis in the presence of lymphoid engraftment. Br J Haematol. 2002;118:108–116
  7. Cavazzana-Calvo M, Fromont C, Le Deist F, et al.  Specific elimination of alloreactive T cells by an anti-interleukin-2 receptor B chain-specific immunotoxin. Transplantation. 1990;50:1–7
  8. Cavazzana-Calvo M, Stephan JL, Sarnacki S, et al.  Attenuation of graft-versus-host disease and graft rejection by ex vivo immunotoxin elimination of alloreactive T cells in an H-2 haplotype disparate mouse combination. Blood. 1994;83:288–298
  9. Mavroudis DA, Jiang YZ, Hensel N, et al.  Specific depletion of alloreactivity against haplotype mismatched related individuals by a recombinant immunotoxin (a new approach to graft-versus-host disease prophylaxis in haploidentical bone marrow transplantation). Bone Marrow Transplant. 1996;17:793–799
  10. Mavroudis DA, Dermime S, Molldrem J, et al.  Specific depletion of alloreactive T cells in HLA-identical siblings (a method for separating graft-versus-host and graft-versus-leukaemia reactions). Br J Haematol. 1998;101:565–570
  11. Amrolia PJ, Muccioli-Casadei G, Yvon E, et al.  Selective depletion of donor allo-reactive T-cells without loss of anti-viral or anti-leukemic responses. Blood. 2003;102:2292–2299
  12. Fehse B, Frerk O, Goldmann M, Bulduk M, Zander AR. Efficient depletion of alloreactive donor T lymphocytes based on expression of two activation-induced antigens (CD25 and CD69). Br J Haematol. 2000;109:644–651
  13. Hartwig UF, Robbers M, Wickenhauser C, Huber C. Murine acute graft-versus-host disease can be prevented by depletion of alloreactive T lymphocytes using activation-induced cell death. Blood. 2002;99:3041–3049
  14. Chen BJ, Cui X, Liu C, Chao NJ. Prevention of graft-versus-host disease while preserving graft-versus-leukemia effect after selective depletion of host-reactive T cells by photodynamic cell purging process. Blood. 2002;99:3083–3088
  15. Squifflet JP, Legendre C. The economic value of valacyclovir prophylaxis in transplantation. J Infect Dis. 2002;186(suppl 1):S116–S122
  16. Meyers JD, Flournoy N, Thomas ED. Risk factors for cytomegalovirus infection after human marrow transplantation. J Infect Dis. 1986;153:478–488
  17. Prentice HG, Gluckman E, Powles RL, et al.  Impact of long-term acyclovir on cytomegalovirus infection and survival after allogeneic bone marrow transplantation. European Acyclovir for CMV Prophylaxis Study Group. Lancet. 1994;343:749–753
  18. Ljungman P. Immune reconstitution and viral infections after stem cell transplantation. Bone Marrow Transplant. 1998;21(suppl 2):S72–S74
  19. Bacigalupo A. Second EBMT Workshop on reduced intensity allogeneic hemopoietic stem cell transplants (RI-HSCT). Bone Marrow Transplant. 2002;29:191–195
  20. Gillespie GM, Wills MR, Appay V, et al.  Functional heterogeneity and high frequencies of cytomegalovirus-specific CD8(+) T lymphocytes in healthy seropositive donors. J Virol. 2000;74:8140–8150
  21. Gamadia LE, Remmerswaal EB, Weel JF, Bemelman F, van Lier RA, Ten Berge IJ. Primary immune responses to human CMV (a critical role for IFN-gamma-producing CD4+ T cells in protection against CMV disease). Blood. 2003;101:2686–2692
  22. Zajac AJ, Blattman JN, Murali-Krishna K, et al.  Viral immune evasion due to persistence of activated T cells without effector function. J Exp Med. 1998;188:2205–2213
  23. Taams LS, Vukmanovic-Stejic M, Smith J, et al.  Antigen-specific T cell suppression by human CD4+CD25+ regulatory T cells. Eur J Immunol. 2002;32:1621–1630
  24. Taylor PA, Lees CJ, Blazar BR. The infusion of ex vivo activated and expanded CD4(+)CD25(+) immune regulatory cells inhibits graft-versus-host disease lethality. Blood. 2002;99:3493–3499
  25. Craston R, Koh M, McDermott A, Ray N, Prentice HG, Lowdell MW. Temporal dynamics of CD69 expression on lymphoid cells. J Immunol Methods. 1997;209:37–45
  26. Bishara A, Brautbar C, Nagler A, et al.  Prediction by a modified mixed leukocyte reaction assay of graft-versus-host disease and graft rejection after allogeneic bone marrow transplantation. Transplantation. 1994;57:1474–1479
  27. Currier JR, Kuta EG, Turk E, et al.  A panel of MHC class I restricted viral peptides for use as a quality control for vaccine trial ELISPOT assays. J Immunol Methods. 2002;260:157–172
  28. Longmate J, York J, La Rosa C, et al.  Population coverage by HLA class-I restricted cytotoxic T-lymphocyte epitopes. Immunogenetics. 2001;52:165–173
  29. Wills MR, Carmichael AJ, Mynard K, et al.  The human cytotoxic T-lymphocyte (CTL) response to cytomegalovirus is dominated by structural protein pp65 (frequency, specificity, and T-cell receptor usage of pp65-specific CTL). J Virol. 1996;70:7569–7579
  30. Tan LC, Gudgeon N, Annels NE, et al.  A re-evaluation of the frequency of CD8+ T cells specific for EBV in healthy virus carriers. J Immunol. 1999;162:1827–1835
  31. Hewitt CR, Feldmann M. Human T cell clones present antigen. J Immunol. 1989;143:762–769
  32. Sidhu S, Deacock S, Bal V, Batchelor JR, Lombardi G, Lechler RI. Human T cells cannot act as autonomous antigen-presenting cells, but induce tolerance in antigen-specific and alloreactive responder cells. J Exp Med. 1992;176:875–880
  33. Solomon SR, Tran T, Carter CS, et al.  Optimized clinical-scale culture conditions for ex vivo selective depletion of host-reactive donor lymphocytes (a strategy for GvHD prophylaxis in allogeneic PBSC transplantation). Cytotherapy. 2002;4:395–406
  34. Davies JK, Koh MB, Prentice HG, Lowdell MW. Potentiating the MLR prior to selective depletion of alloreactive cells. Biol Blood Marrow Transplant. 2002;9:67; (abstr.)
  35. Jiang YZ, Mavroudis DA, Dermime S, Molldrem J, Hensel NF, Barrett AJ. Preferential usage of T cell receptor (TCR) V beta by allogeneic T cells recognizing myeloid leukemia cells (implications for separating graft-versus-leukemia effect from graft-versus-host disease). Bone Marrow Transplant. 1997;19:899–903
  36. Dolstra H, Fredrix H, Preijers F, et al.  Recognition of a B cell leukemia-associated minor histocompatibility antigen by CTL. J Immunol. 1997;158:560–565
  37. Dolstra H, Fredrix H, Maas F, et al.  A human minor histocompatibility antigen specific for B cell acute lymphoblastic leukemia. J Exp Med. 1999;189:301–308
  38. Lechner F, Cuero AL, Kantzanou M, Klenerman P. Studies of human antiviral CD8+ lymphocytes using class I peptide tetramers. Rev Med Virol. 2001;11:11–22
  39. Kern F, Surel IP, Faulhaber N, et al.  Target structures of the CD8(+)-T-cell response to human cytomegalovirus (the 72-kilodalton major immediate-early protein revisited). J Virol. 1999;73:8179–8184
  40. Khanna R, Burrows SR. Role of cytotoxic T lymphocytes in Epstein-Barr virus-associated diseases. Ann Rev Microbiol. 2000;54:19–48
  41. Alwan WH, Record FM, Openshaw PJ. CD4+ T cells clear virus but augment disease in mice infected with respiratory syncytial virus. Comparison with the effects of CD8+ T cells. Clin Exp Immunol. 1992;88:527–536
  42. Walls T, Shankar AG, Shingadia D. Adenovirus (an increasingly important pathogen in paediatric bone marrow transplant patients). Lancet Infect Dis. 2003;3:79–86
  43. Papadopoulos EB, Ladanyi M, Emanuel D, et al.  Infusions of donor leukocytes to treat Epstein-Barr virus-associated lymphoproliferative disorders after allogeneic bone marrow transplantation. N Engl J Med. 1994;330:1185–1191
  44. Kishi Y, Kami M, Oki Y, et al.  Donor lymphocyte infusion for treatment of life-threatening respiratory syncytial virus infection following bone marrow transplantation. Bone Marrow Transplant. 2000;26:573–576
  45. Hromas R, Cornetta K, Srour E, Blanke C, Broun ER. Donor leukocyte infusion as therapy of life-threatening adenoviral infections after T-cell-depleted bone marrow transplantation. Blood. 1994;84:1689–1690
  46. Wood KJ, Sakaguchi S. Regulatory T cells in transplantation tolerance. Nat Rev Immunol. 2003;3:199–210
  47. Papiernik M. Natural CD4+ CD25+ regulatory T cells. Their role in the control of superantigen responses. Immunol Rev. 2001;182:180–189
  48. Drobyski WR, Potluri J, Sauer D, Gottschall JL. Autoimmune hemolytic anemia following T cell-depleted allogeneic bone marrow transplantation. Bone Marrow Transplant. 1996;17:1093–1099

PII: S1083-8791(03)00522-6

doi: 10.1016/j.bbmt.2003.12.001

Biology of Blood and Marrow Transplantation
Volume 10, Issue 4 , Pages 259-268 , April 2004

Article Tools

* Image Usage & Resolution